{"id":"W2909653713","doi":"10.1371/journal.pone.0210417","title":"A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies","year":2019,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada); University of Calgary; Université de Montréal; Hôpital Notre-Dame","funders":"Health Canada; EMD Serono; Novartis Pharmaceuticals Canada; Multiple Sclerosis Society of Canada; Canadian Institutes of Health Research; Teva Pharmaceutical Industries; Multiple Sclerosis Society; Biogen","keywords":"Fingolimod; Medicine; Discontinuation; Natalizumab; Medical prescription; Internal medicine; Multiple sclerosis; Retrospective cohort study; Teriflunomide; Disease; Pharmacology; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003184868,0.0004011063,0.0005765527,0.002634479,0.001656598,0.001128728,0.001363472,0.0007153344,0.001277869],"category_scores_gemma":[0.01070913,0.0004833936,0.001314581,0.007031171,0.0005541648,0.0003697949,0.0007208861,0.000749052,0.0001895343],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01092875,"about_ca_system_score_gemma":0.0119166,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8977262,"about_ca_topic_score_gemma":0.8188227,"domain_scores_codex":[0.9951656,0.0006222656,0.0006284509,0.0005630761,0.002474457,0.0005461735],"domain_scores_gemma":[0.9841515,0.00177005,0.007911039,0.0009355515,0.004360483,0.0008714288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000118458,0.00003102664,0.9981987,0.00001990581,0.00009048813,0.00003011427,0.0001005162,0.00005880644,0.00004176635,0.00001841866,0.0002289085,0.001062823],"study_design_scores_gemma":[0.0000169523,0.00004575309,0.9987193,0.00001368049,0.00005257638,0.00009153983,0.0001217551,0.0005457384,0.00004329556,0.000007118038,0.0003339299,0.000008251991],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919655,0.000387932,0.000165278,0.0001151675,0.000005114746,0.00008384792,0.006436895,0.00001292334,0.0008273401],"genre_scores_gemma":[0.9947102,0.0002450734,0.000286262,0.00009954995,0.00001099311,0.00005796804,0.004361382,0.000004987962,0.0002235529],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1022738,"threshold_uncertainty_score":0.2057521,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07095431348400053,"score_gpt":0.2567720662914748,"score_spread":0.1858177528074742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}